Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe

European Journal of Cancer

Volumn 60, Issue , 2016, Pages 179-189

  Harries, Mark ^a   Malvehy, Josep ^b   Lebbe, Céleste ^c   Heron, Louise ^d   Amelio, Justyna ^e   Szabo, Zsolt ^f   Schadendorf, Dirk ^g  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

^c SAINT LOUIS HOSPITAL   (France)

^d ADELPHI REAL WORLD   (United Kingdom)

^e AMGEN LTD   (United Kingdom)

^f AMGEN INC   (United States)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; DENDRITIC CELL VACCINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; PACLITAXEL; TEMOZOLOMIDE; VEMURAFENIB; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL PRACTICE; FRANCE; GERMANY; HUMAN; ITALY; MELANOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; UNITED KINGDOM; CLINICAL DECISION MAKING; CLINICAL PATHWAY; EPIDEMIOLOGY; EUROPE; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PRACTICE GUIDELINE; PROCEDURES; SKIN NEOPLASMS; STANDARDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL DECISION-MAKING; CRITICAL PATHWAYS; EPIDEMIOLOGIC METHODS; EUROPE; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; SKIN NEOPLASMS;

EID: 84966309561     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.01.011     Document Type: Review

References (43)

1. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 Dec 20 2009 6199 6206
2. S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini, R. Zanetti, C. Masini, and et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors Eur J Cancer 41 14 Sep 2005 2040 2059
3. S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini, O. Picconi, P. Boyle, and et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure Eur J Cancer 41 1 Jan 2005 45 60
4. D.C. Whiteman, P. Watt, D.M. Purdie, M.C. Hughes, N.K. Hayward, and A.C. Green Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma J Natl Cancer Inst 95 11 Jun 4 2003 806 812
5. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 Mar 2010 765 781
6. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 6 Apr 2013 1374 1403
7. F. Erdmann, J. Lortet-Tieulent, J. Schuz, H. Zeeb, R. Greinert, E.W. Breitbart, and et al. International trends in the incidence of malignant melanoma 1953-2008 - are recent generations at higher or lower risk? Int J Cancer 132 2 Jan 15 2013 385 400
8. A.C. Geller, and G.D. Annas Epidemiology of melanoma and nonmelanoma skin cancer Semin Oncol Nurs 19 1 Feb 2003 2 11
9. E. de Vries, F.I. Bray, J.W. Coebergh, and D.M. Parkin Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia Int J Cancer 107 1 Oct 20 2003 119 126
10. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 Sep 2 2004 998 1012
11. C.C. Lee, M.B. Faries, L.A. Wanek, and D.L. Morton Improved survival for stage IV melanoma from an unknown primary site J Clin Oncol 27 21 Jul 20 2009 3489 3495
12. R. Dummer, A. Hauschild, M. Guggenheim, U. Keilholz, G. Pentheroudakis, and E.G.W. Group Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 Oct 2012 vii86 vii91
13. C. Garbe, K. Peris, A. Hauschild, P. Saiag, M. Middleton, A. Spatz, and et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-update 2012 Eur J Cancer 48 15 Oct 2012 2375 2390
14. European Medicines Agency (EMA) Opdivo (nivolumab) summary of product characteristics 2015 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003985/WC500189765.pdf Accessed November 2015
15. European Medicines Agency (EMA) Keytruda (pembrolizumab) summary of product characteristics 2015 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003820/WC500190990.pdf Accessed November 2015
16. C. Bedane, M.T. Leccia, B. Sassolas, B. Bregman, C. Lebbe French investigators of the Ms Treatment patterns and outcomes in patients with advanced melanoma in France Curr Med Res Opin 29 10 Oct 2013 1297 1305
17. V. Chiarion-Sileni, M. Guida, A. Romanini, M.G. Bernengo, P. Ascierto, P. Queirolo, and et al. Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma Dermatology 226 Suppl. 1 2013 22 27
18. K. Johnston, A.R. Levy, P. Lorigan, M. Maio, C. Lebbe, M. Middleton, and et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study) Eur J Cancer 48 14 September 2012 2175 2182
19. C. Lebbe, P. Lorigan, P. Ascierto, A. Testori, C. Bedane, M. Middleton, and et al. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study) Eur J Cancer 48 17 2012 3205 3214
20. P. Lorigan, M. Marples, M. Harries, J. Wagstaff, A.G. Dalgleish, R. Osborne, and et al. Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study Br J Dermatol 170 1 2014 87 95
21. Agenzia Nazionale per Servizi Sanitari Regionali Diagnosi e terapia del melanoma cutaneo: linee guida nazionali di riferimento 2012 http://www.lamiapelle.salute.gov.it/imgs/C-17-downloadMiaPelle-3-allegati-itemAllegati-0-allegato.pdf Accessed July 2015
22. Associazione Italiana di Oncologia Medica Linee guida: melanoma 2014 http://www.aiom.it/C-Common/Download.asp?file=/$Site$/Attivita-Scientifica/Linee-Guida/2013/Melanoma-v6-24.09.13.pdf Accessed July 2015
23. Grupo Espanol Multidisciplinar de Melanoma La calidad en la atención a pacientes con melanoma cutáneo proceso de atención al paciente con melanoma cutáneo sociedad 2012 http://calidadasistencial.es/wp-seca/wp-content/uploads/2015/02/350-melanoma-cutaneo.pdf Accessed July 2015
24. M.T. Leccia, F. Planchamp, B. Sassolas, P. Combemale, P. Modiano, C. Bedane, and et al. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute] Ann Dermatol Venereol 141 2 Feb 2014 111 121
25. London Cancer Alliance (LCA) London Cancer Alliance (LCA) Skin Cancer Clinical Guidelines, July 2014 2014
26. J.R. Marsden, J.A. Newton-Bishop, L. Burrows, M. Cook, P.G. Corrie, N.H. Cox, and et al. Revised UK guidelines for the management of cutaneous melanoma 2010 J Plast Reconstr Aesthet Surg 63 9 Sep 2010 1401 1419
27. A. Pflugfelder, C. Kochs, A. Blum, M. Capellaro, C. Czeschik, T. Dettenborn, and et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma" J Dtsch Dermatol Ges 11 Suppl. 6 Aug 2013 111 116 111-126
28. A. Bilitou, Z. Zhao, B.L. Barber, G.S. Clapton, and D. Saltman Patterns of pharmaceutical therapy in advanced melanoma 2013 Paper presented at: journal of clinical oncology
29. C.F. Jones, Z. Zhao, B.L. Barber, M. Bagijn, and D. Saltman Current management of advanced melanoma: a European perspective 2013 Paper presented at: journal of clinical oncology
30. D. Schadendorf, J. Vaubel, E. Livingstone, and L. Zimmer Advances and perspectives in immunotherapy of melanoma Ann Oncol 23 Suppl. 10 Sep 2012 x104 x108
31. S. Bhatia, S.S. Tykodi, and J.A. Thompson Treatment of metastatic melanoma: an overview Oncol Williston Park 23 6 May 2009 488 496
32. Committee for Medicinal Products for Human Use (CHMP) First oncolytic immunotherapy medicine recommended for approval 2015 http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2015/10/news-detail-002421.jsp&mid=WC0b01ac058004d5c1 Accessed November 2015
33. Agence nationale de sécurité du médicament et des produits de santé (ANSM) Cobimetinib 20 mg comprimés pelliculés 2015 http://ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/ATU-de-cohorte-en-cours/Liste-des-ATU-de-cohorte-en-cours/COBIMETINIB-20-nbsp-mg-comprimes-pellicules Accessed September 2015
34. ClinicalTrials.gov Access study of trametinib for subjects with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma 2015 https://clinicaltrials.gov/ct2/show/NCT02416232 Accessed September 2015
35. European Medicines Agency (EMA) Mekinist (trametinib) summary of product characteristics 2015 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002643/WC500169657.pdf Accessed November 2015
36. European Medicines Agency (EMA) Tafinlar (dabrafenib) summary of product characteristics 2015 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002604/WC500149671.pdf Accessed November 2015
37. ®, first combination approved for patients with aggressive form of melanoma 2015 [press release]
38. Roche CHMP recommends EU approval for Roche's combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) in advanced melanoma 2015 http://www.roche.com/media/store/releases/med-cor-2015-09-25.htm Accessed October 2015
39. Agence nationale de sécurité du médicament et des produits de santé (ANSM) Nivolumab 10 mg/ml, solution à diluer pour perfusion 2015 http://ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/ATU-de-cohorte-en-cours/Liste-des-ATU-de-cohorte-en-cours/NIVOLUMAB-10-mg-ml-solution-a-diluer-pour-perfusion Accessed September 2015
40. Agence nationale de sécurité du médicament et des produits de santé (ANSM) Pembrolizumab MSD France 50 mg, poudre pour solution pour perfusion 2015 http://ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/ATU-de-cohorte-en-cours/Liste-des-ATU-de-cohorte-en-cours/PEMBROLIZUMAB-MSD-FRANCE-50-mg-poudre-pour-solution-pour-perfusion Accessed September 2015
41. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Pembrolizumab - nutzenbewertung gemäß § 35a SGB V 2015 https://www.g-ba.de/downloads/92-975-937/2015-11-12-Nutzenbewertung-IQWiG-Pembrolizumab.pdf Accessed November 2015
42. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Nivolumab - nutzenbewertung gemäß § 35a SGB V 2015 https://www.g-ba.de/downloads/92-975-891/2015-10-13-Nutzenbewertung-IQWiG-Nivolumab.pdf Accessed November 2015
43. ClinicalTrials.gov NCT02083484: program for pembrolizumab (MK-3475) in participants with metastatic melanoma who have failed standard of care therapy including ipilimumab (MK-3475-030) 2015 https://clinicaltrials.gov/ct2/show/NCT02083484 Accessed October 2015